Gastric Cancer Market Report 2026

Gastric Cancer Market Overview

• Gastric Cancer market size has reached to $3.64 billion in 2025 • Expected to grow to $7.29 billion in 2030 at a compound annual growth rate (CAGR) of 14.8% • Growth Driver: Impact Of Rising Obesity Rates On Gastric Cancer Treatment Demand • Market Trend: Advancements In Personalized Treatment For Gastric And GEJ Adenocarcinoma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastric Cancer Market?

Gastric cancer is a malignant tumor that originates in the lining of the stomach. It often begins in the mucosa, the innermost layer of the stomach, and can spread to deeper layers, nearby tissues, or distant organs if not treated early. The disease is commonly associated with risk factors such as chronic infection with helicobacter pylori, smoking, excessive alcohol consumption, poor diet, and genetic predisposition. The main types of gastric cancers are adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma is the most common type of gastric cancer, originating in the glandular cells of the stomach lining. It is diagnosed using endoscopy, biopsy, imaging tests, exploratory surgery, and others, and is treated by surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and others. It is distributed through various channels such as hospital pharmacies, specialty and retail pharmacies, and others.

What Is The Gastric Cancer Market Growth Forecast?

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $7.29 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to advancements in immuno-oncology, growth in precision diagnostics, rising cancer screening programs, increasing aging population, development of novel targeted drugs. Major trends in the forecast period include rising adoption of targeted and immunotherapies, increased focus on early diagnosis and screening, expansion of personalized cancer treatment approaches, growing use of combination therapy regimens, improved multidisciplinary cancer care models.

Global Gastric Cancer Market Segmentation

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types 2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis 3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments 4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma 2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma 3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST 4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3 5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

What Is The Driver Of The Gastric Cancer Market?

The rising obesity rates are expected to propel the growth of the gastric cancer market going forward. Obesity is a medical condition characterized by excessive body fat accumulation, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health problems. Obesity rates are rising due to factors such as poor diet, lack of physical activity, sedentary lifestyles, environmental influences, and genetic predispositions. Excess body fat, particularly visceral fat around the abdomen, is associated with a higher risk of developing gastric cancer, as obesity triggers chronic inflammation and metabolic disturbances, both linked to cancer development, contributing to a rise in the demand for gastric cancer treatment. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that one in eight people worldwide now live with obesity, exceeding 1 billion individuals. Therefore, the rising obesity rates are driving the gastric cancer industry.

Key Players In The Global Gastric Cancer Market

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Taiho Oncology Inc., Taiho Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biocon Limited, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd

Global Gastric Cancer Market Trends and Insights

Major companies operating in the gastric cancer market are focusing on developing technologically advanced solutions, such as companion diagnostic assays, to help ensure personalized treatment. A companion diagnostic assay is a test used to identify patients who are most likely to benefit from a specific therapeutic treatment based on the presence of certain biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. This assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18. 2. Utilizing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, the test advances personalized healthcare, expanding treatment options for gastric and GEJ adenocarcinoma.

What Are Latest Mergers And Acquisitions In The Gastric Cancer Market?

In January 2023, Leap Therapeutics, Inc., a U.S.-based biotechnology company focused on targeted oncology therapies, acquired Flame Biosciences, Inc. for an undisclosed amount. With this acquisition, Leap sought to bolster its oncology pipeline by integrating Flame’s clinical-stage anti-Claudin 18.2 antibody program, FL-301, thereby gaining exposure to a validated gastric (and pancreatic) cancer antigen. Flame Biosciences, a US-based company, is developing precision cancer therapeutics, including its Claudin 18.2-targeted antibody, which is particularly relevant for gastric/gastroesophageal cancer indications.

Regional Outlook

North America was the largest region in the gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastric Cancer Market?

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastric Cancer Market Report 2026?

The gastric cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.